Last reviewed · How we verify

NCT03591640

The Validity of Kleinhauer Betke in Women With Known Hemoglobinopathy for Fetal-maternal Hemorrhage

Completed NA Last updated 28 June 2022
What this trial tests

NA trial testing Blood test in Fetal-Maternal Hemorrhage in 27 participants. Completed in 28 April 2021.

Timeline
18 July 2018
Primary endpoint
28 April 2021
28 April 2021

Quick facts

Lead sponsorHillel Yaffe Medical Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment27
Start date18 July 2018
Primary completion28 April 2021
Estimated completion28 April 2021
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Hillel Yaffe Medical Center

Who can join

18 and older, female only, with Fetal-Maternal Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to determine the validity of Kleinhauer Betke in women with known hemoglobinopathy for fetal-maternal hemorrhage.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood test

Trials testing the same drug.

Other Hillel Yaffe Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03591640.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing